Is Trevi Therapeutics (TRVI) Building a Multi-Indication Moat With Its Nalbuphine ER Cough Strategy?

Trevi Therapeutics recently outlined past and upcoming milestones for its chronic cough portfolio, including an FDA ...
Seeking Alpha

Altimmune outlines phase 3 pemvidutide plans and expands to alcohol-related liver indications while extending cash runway

CEO Vipin Garg highlighted the imminent readout of the IMPACT Phase 2b NASH trial, stating "we are confident of achieving the trial’s key efficacy and safety objectives" and emphasized that if ...

Tenax Therapeutics: How Lower Variance In Phase 3 Has "Loaded The Dice" For An Asymmetric Repricing

The market underappreciates TENX's late-stage pipeline and risk-adjusted asset value; we recommend buying ahead of Phase 3 ...
Nasdaq

Crinetics Initiates Phase 3 Trial Of Paltusotine For A New Indication In Carcinoid Syndrome

(RTTNews) - Crinetics Pharmaceuticals Inc. (CRNX) has begun its pivotal Phase 3 trial of Paltusotine in adults with carcinoid syndrome, dubbed CAREFNDR. Carcinoid syndrome affects about 20% of ...
WDTN

Milvexian Granted U.S. FDA Fast Track Designation for All Three Indications Under Evaluation in Phase 3 Librexia Program: Ischemic Stroke, Acute Coronary Syndrome and Atrial ...

The Librexia program evaluating milvexian is unrivaled as the most comprehensive factor XIa inhibitor clinical development program to date and will provide extensive data from nearly 50,000 patients, ...
Fierce Biotech

Hutchmed heats up autoimmune race with phase 3 win, teeing up China filing

Hutchmed has continued to test sovleplenib in wAIHA in parallel, culminating in the delivery of data from a Chinese phase 3 ...